The future of early endpoints for neoadjuvant therapy.

CPS + EG and Neo-Bioscore scores are linked to long-term outcomes at the patient level, but they do not predict long-term outcomes at the trial level in neoadjuvant therapy studies.

• Why it matters: Surrogate early endpoints are needed to assess treatment efficacy faster, yet current scores may fail to generalize across trials, limiting reliable evaluation.
• What they did: Conforti et al. evaluated whether CPS + EG and Neo-Bioscore predict long-term outcomes, comparing performance at the patient level versus the trial level.
• The result: The patient-level predictive link suggests these scores can reflect efficacy for individuals, while the lack of trial-level prediction implies early endpoints must be improved to work consistently across trials.

AI summary of the abstract · may contain errors · not medical advice · read the paper.